Compare FFIN & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIN | XENE |
|---|---|---|
| Founded | 1890 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | 1994 | 2014 |
| Metric | FFIN | XENE |
|---|---|---|
| Price | $31.70 | $55.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $36.50 | ★ $68.55 |
| AVG Volume (30 Days) | 612.9K | ★ 782.3K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 13.46 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $6.61 | $2,496.48 |
| P/E Ratio | $62.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.12 | $28.19 |
| 52 Week High | $38.74 | $62.91 |
| Indicator | FFIN | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 46.00 |
| Support Level | $31.21 | $52.92 |
| Resistance Level | $31.74 | $56.66 |
| Average True Range (ATR) | 0.72 | 1.99 |
| MACD | -0.12 | -0.28 |
| Stochastic Oscillator | 38.16 | 35.37 |
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.